Furthermore, it has been proposed that specific mAR-activating ligands, namely testosterone-serum albumin conjugates, may be developed as novel drug candidates for the treatment of mAR+ prostate tumors [17,18]. This evidence concerns the gene ALB and prostate neoplasm.